Immuun interventie met tolerogene dendritische cellen (DC) in type 1 diabetes. Eerste klinische veiligheidsstudie genaamd D-sense
Recruiting
- Conditions
- Diabetes Mellitus, Type 1ImmunotherapyDendritic cellsSafetyType 1 diabetesImmunotherapieDendritische cellenVeiligheid
- Registration Number
- NL-OMON21892
- Lead Sponsor
- eiden Universitu Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 9
Inclusion Criteria
• Age 18-50 years;
• Diagnosis of type 1 Diabetes Mellitus at least 18 months (dated from the first insulin injection);
Exclusion Criteria
• Use of immunosuppressive or immunomodulatory therapies, including systemic steroids within 1 month prior to
enrolment and/or prior monoclonal antibody therapy of any type given for any indication at any time;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method